Last reviewed · How we verify
Cialis
At a glance
| Generic name | Cialis |
|---|---|
| Also known as | Tadalafil |
| Sponsor | Ottawa Hospital Research Institute |
| Target | Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Benign prostatic hyperplasia
- Impotence
- Pulmonary hypertension
Common side effects
- Headache
- Back pain
- Myalgia
- Dyspepsia
- Nasal congestion
- Flushing
- Pain in limb
- Nausea
- Vomiting
- Upper abdominal pain
- Arthralgia
- Muscle spasm
Key clinical trials
- Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PHASE3)
- Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate (PHASE1)
- Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension (NA)
- Double j Stent Related Symptoms (EARLY_PHASE1)
- Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (PHASE2)
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (PHASE2)
- Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |